11/1612015
`
`ISTA Pharmaceuticals Announces XIBROM (TM) Shipments to- Bloomberg
`
`Bloomberg.com
`Businessweekcom
`Bloomberg TV
`Premium
`
`• Professional Products
`• Bloomberg Anvwhere
`• Bloomberg Tradebook
`
`Industry Products
`
`• Bloomberg Briefs
`• Bloomberg Government
`• Bloomberg Law
`• Bloomberg BNA
`• Bloomberg New Energy Finance
`• Bloomberg Sports
`
`Enterprise Products
`
`• Compliance Solutions
`• Data Solutions
`• Technology Solutions
`• Trading Solutions
`
`• Register
`• Sign In
`
`Market Snapshot
`• us_
`• Europe
`• Asia
`
`Ticker Volume PricePrice Delta
`DJIA
`18,135.5315.750.09%
`S&P 500 2,122.56 -0.29-0.01%
`NASDA05,154.28 0.31 0.01%
`Ticker Volume PricePrice Delta
`STOXX 503,625.97 29.900.83%
`FTSE 100 6,834.87 9.20 0.13%
`DAX
`11,542.5482.040.72%
`Ticker
`Volume Price Price Delta
`NIKKEI
`20,809.42381.231.87%
`TOPIX
`1,676.40 27.79 1.69%
`33.46252.610.93%
`
`CUSTOMER CARE
`Customer Care and social media: the next generation
`How Customer Care is harnessing the power of machine learning.
`
`Bloomberg
`
`• Our Company
`
`http://www .bloomberg_com/apps/news?pid=newsarchive&sid=atlsoW6E1a Tw
`
`1/8
`
`PAGE 1 OF 8
`
`SENJU EXHIBIT 2185
`INNOPHARMA v SENJU
`IPR2015-00903
`
`

`
`11/16/2015
`
`ISTA Pharmaceuticals Announces XIBROM(TM) Shipments to ­ Bloomberg
`
`Professional
`Anywhere
`
`Search News, Quotes and O
`
`Bloomberg Homepage
`More
`Mobile Apps
`Businessweek.com
`Insights Series
`Bloomberg Blog
`
`Home
`
`Quick
`News
`
`Top Headlines
`Most Popular
`Exclusive
`Law
`Entrepreneurs
`Leaders
`Arts & Culture
`Economy
`Environment
`Science
`Sports
`Markets Magazine
`Regions
`U.S.
`China
`Europe
`Asia
`U.K. & Ireland
`Australia & New Zealand
`Canada
`India & Pakistan
`Japan
`Africa
`Eastern Europe
`More Regions
`Markets
`Commodities
`Currencies
`Bonds
`Stocks
`Energy Markets
`Municipal Bonds
`Emerging Markets
`Funds
`Islamic Finance
`More Markets
`Industries
`Energy
`Technology
`Real Estate
`http://www.bloomberg.com/apps/news?pid=newsarchive&sid=atLsoW6E1aTw
`
`2/8
`
`PAGE 2 OF 8
`
`

`
`11/16/2015
`
`ISTA Pharmaceuticals Announces XIBROM(TM) Shipments to ­ Bloomberg
`
`Finance
`Health Care
`Transportation
`Insurance
`Retail
`Media
`More Industries
`
`Opinion
`Editorials
`Columns
`Op­Eds
`Business Class
`Echoes
`The Ticker
`World View
`Market Data
`Stocks
`Stock Futures
`World Indexes
`Gainers & Losers
`Regional Indexes
`Earnings
`Rates & Bonds
`Government Bonds
`Corporate Bonds
`Key Rates
`Commodities
`Commodity Futures
`Energy Prices
`Currencies
`World Currencies
`Foreign Exchange Rates
`
`ETFs
`Mutual Funds
`Economic Calendar
`Forex Trading Videos
`Personal Finance
`Overview
`Saving & Investing
`Real Estate
`Retirement Planning
`Financial Advisers
`Taxes
`Real Cost Of
`Money Gallery
`Insurance & Health
`Portfolio Impact
`Calculators
`Portfolio Tracker
`
`Tech
`
`Overview
`Social Media
`Mobile & Wireless
`Web
`http://www.bloomberg.com/apps/news?pid=newsarchive&sid=atLsoW6E1aTw
`
`3/8
`
`PAGE 3 OF 8
`
`

`
`11/16/2015
`
`ISTA Pharmaceuticals Announces XIBROM(TM) Shipments to ­ Bloomberg
`Enterprise Tech
`TV, Games & Movies
`Apple
`Tech Deals
`Tech Blog
`Slideshows
`Videos
`
`Politics
`Overview
`Elections
`White House
`Congress
`State & Local
`Political Capital
`Videos
`Live Blogs
`Sustainability
`Overview
`Energy
`Corporate Sustainability
`Policy
`Natural Resources
`Health & Population
`Slideshows
`Videos
`Blog: The Grid
`
`TV
`
`Live TV
`Channel Finder
`Personalities
`iPad App
`Schedule
`U.S.
`Asia
`Europe
`Shows
`Surveillance
`Market Makers
`Lunch Money
`Street Smart
`Bloomberg West
`Game Changers
`More Shows
`
`Must See
`Latest
`Most Watched
`Interviews
`
`Video
`
`Radio
`
`Live Radio
`Shows
`Schedule
`Personalities
`Podcasts
`http://www.bloomberg.com/apps/news?pid=newsarchive&sid=atLsoW6E1aTw
`
`4/8
`
`PAGE 4 OF 8
`
`

`
`11/16/2015
`
`ISTA Pharmaceuticals Announces XIBROM(TM) Shipments to ­ Bloomberg
`
`First Word
`Surveillance
`Taking Stock
`More Podcasts
`
`ISTA Pharmaceuticals Announces XIBROM(TM)
`Shipments to
`
`ISTA Pharmaceuticals Announces XIBROM(TM) Shipments to Wholesalers to End on February 28, 2011
`
`BROMDAY(TM) Launch On Track ­­ Capturing 46% of Weekly New Prescriptions in the Bromfenac
`Franchise by the End of January
`
`IRVINE, CA ­­ (Marketwire) ­­ 02/08/11 ­­ ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today announced
`that due to the rapid adoption of BROMDAY(TM) (bromfenac ophthalmic solution) 0.09%, the first and only
`once­daily non­steroidal anti­inflammatory (NSAID) prescription eye drop for the treatment of postoperative
`inflammation and reduction of ocular pain in patients who have undergone cataract extraction, the company will
`stop selling twice­daily XIBROM (bromfenac ophthalmic solution)(R) 0.09%. ISTA no longer plans to supply
`XIBROM to pharmaceutical wholesalers after February 28, 2011. For approximately 2­3 weeks thereafter, there
`will be a limited supply of XIBROM available at wholesalers and pharmacies to fill remaining XIBROM
`prescriptions. ISTA anticipates wholesalers will continue to sell XIBROM to pharmacies until their inventory is
`depleted.
`
`As of Fall of 2010, according to data from IMS, twice­daily XIBROM (bromfenac ophthalmic solution)(R)
`0.09% had become the most prescribed branded ocular NSAID in the U.S. market for use following cataract
`surgery. Last October, ISTA received U.S. Food and Drug Administration (FDA) approval for
`BROMDAY(TM), a once­daily formulation of bromfenac. BROMDAY has been granted three years of
`marketing exclusivity as provided under the Drug Price Competition and Patent Term Restoration Act,
`commonly known as the Hatch­Waxman Act. Under the Hatch­Waxman Act, the FDA may not approve an
`Abbreviated New Drug Application for a generic version of BROMDAY until October 2013. ISTA launched
`BROMDAY at the end of November 2010 and, since that time, has focused most of the sales team's efforts on
`converting physicians who prescribed XIBROM to prescribing BROMDAY.
`
`"The transition to BROMDAY has been swift. As of the last week in January, 46% of the XIBROM new
`prescriptions have been converted over to BROMDAY, according to weekly prescription data supplied by
`IMS," stated Vicente Anido, Jr., PhD, President and Chief Executive Officer of ISTA Pharmaceuticals. "Having
`the first and only once­a­day NSAID for postoperative inflammation and reduction of ocular pain in patients
`who have undergone cataract extraction has proven to be a major differentiation in the eyes of our customers
`and their patients. We look forward to gaining even wider acceptance of BROMDAY throughout the
`prescribing ophthalmic community in the years to come."
`
`ABOUT ISTA PHARMACEUTICALS ISTA Pharmaceuticals, Inc., is the fourth largest and fastest growing
`branded prescription eye care business in the United States, with an expanding focus on allergy therapeutics.
`ISTA currently markets five products, including treatments for ocular inflammation and pain post­cataract
`surgery, glaucoma and ocular itching associated with allergic conjunctivitis. The company's development
`pipeline contains additional candidates in various stages of development to treat dry eye, ocular inflammation
`and pain and nasal allergies. Headquartered in Irvine, California, the company generated 2009 revenues of $111
`million. For additional information about ISTA Pharmaceuticals, please visit the corporate website at
`www.istavision.com.
`
`http://www.bloomberg.com/apps/news?pid=newsarchive&sid=atLsoW6E1aTw
`
`5/8
`
`PAGE 5 OF 8
`
`

`
`ISTA Pharmaceuticals Announces XIBROM (TM) Shipments to- Bloomberg
`11/1612015
`BROMDA Y(1M) (bromfenac ophthalmic solution) 0.09% and XIBROM (bromfenac ophthalmic solution)(R)
`0.09%, are trademarks ofiSTA Pharmaceuticals, Inc.
`
`FORWARD-LOOKING STATEMENTS Any statements contained in this press release that refer to future
`events or other non-historical matters are forward-looking statements. Without limiting the foregoing, but by
`way of example, statements contained in this press release related to the end of shipments of XIBROM, supplies
`ofXIBROM, inventories ofXIBROM and future acceptance of BROMDAY are forward-looking statements.
`Except as required by law, ISTA disclaims any intent or obligation to update any forwaTd-looking statements.
`These forward-looking statements are based on ISTA's expectations as of the date of this press release and are
`subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could
`cause actual results to differ fi:om current expectations are detailed from time to time in ISTA's public filings
`with the U.S. Securities and Exchange Commission, including but not limited to ISTA's Annual Report on Form
`10-K for the year ended December 31,2009, and its Qrnuterly Report on Forms 10-Q for the quarters ended
`March 31, June 30 and September 30,2010.
`
`CONTACTS
`
`For Investor Relations: Lauren Silvernail 949-788-5302 lsilvemail@istavision.com
`
`Jeanie Herbert 949-789-3159 jherbett@istavision.com
`
`Juliane Snowden Burns McClellan 212-213-0006 jsnowden@burnsmc.com
`
`For General Media: Justin Jackson Burns McClellan 212-213-0006 jjackson@bumsmc.com
`
`For Trade Media: Tad Heitmann BioComm Network 714-273-2937 theitmann@BioCommNetwork.com
`
`•
`
`• More
`o Business Exchange
`o Buzzup!
`o Digg
`• Print
`• Email
`
`Sponsored Links
`Advertisement
`
`xerox~r
`
`HEALTHCARE
`
`How social factors
`shape population
`health.
`Integrating the non-medical
`sources of health issues.
`
`Read the eBook
`
`Advertisements
`
`http://www .bloomberg.com/apps/news?pid=newsarchive&sid=atlsoW6E1a Tw
`
`6/8
`
`PAGE 6 OF 8
`
`

`
`11/1&'2015
`Sponsored Links
`
`Regis College -
`Masters
`
`ISTA Pharmaceuticals Announces XIBROM(TM) Shipments to - Bloomberg
`
`G> X
`
`regiscollege _edu/graduate
`Earn Your Masters Degree At
`Regis College. Learn More
`Here!
`
`Advertisement
`Bloomberg
`
`• Radio
`• T,ive TV
`
`Bloomberg.com
`
`• News
`• Opinion
`• Markets
`• Personal Finance
`• Tech
`• Sustainabilitv
`• TV
`• Video
`• Radio
`• Archives
`
`About
`
`• About Bloomberg
`• Careers
`• Adve11ising
`• Press Room
`• Trademarks
`• Te1ms of Se1v ice
`• Privacy Policy
`
`Support and Contact
`
`• Customer Suppm1 Contact
`• Feedback
`• Help
`• Sitemap
`
`Stay Connected
`
`http://www _bloomberg.com/apps/news?pid=newsarchive&sid=atlsoW6E1 a Tw
`
`7/8
`
`PAGE 7 OF 8
`
`

`
`11/16/2015
`
`ISTA Pharmaceuticals Announces XIBROM(TM) Shipments to ­ Bloomberg
`
`Twitter
`Facebook
`Linked In
`google+
`StumbleUpon
`
`Bloomberg Terminal
`
`Professional
`Anywhere
`
`Related Bloomberg Sites
`
`Bloomberg Businessweek
`Bloomberg Institute
`ブルームバーグ(日本語)
`会社概要(日本語)
`关于彭博中国
`
`Bloomberg Markets Magazine
`Bloomberg Open Symbology
`Bloomberg Link
`Bloomberg Blog
`Bloomberg Press
`
`Bloomberg Premium Services
`
`Bloomberg Briefs
`Bloomberg Government
`Bloomberg Law
`Bloomberg BNA
`
`Bloomberg New Energy Finance
`Bloomberg Sports
`
`Mobile Apps
`
`Bloomberg
`Bloomberg Radio+
`Bloomberg TV+
`Bloomberg Businessweek+
`
`©2015 BLOOMBERG L.P. ALL RIGHTS RESERVED.
`Jobs by Indeed 
` Rate this Page Made in NYC Ad Choices
`
`http://www.bloomberg.com/apps/news?pid=newsarchive&sid=atLsoW6E1aTw
`
`8/8
`
`PAGE 8 OF 8